Ulrike Tontsch-Grunt

BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy

Frank Hilberg, Gerald J. Roth, Martin Krššák et al. · Cancer Research · 2008 · 1K citations · Full text

Triple Angiokinase Inhibitor, Chemoprevention Strategy, Pathology +18

Transcriptional plasticity promotes primary and acquired resistance to BET inhibition

Philipp Rathert, Mareike Roth, Tobias Neumann et al. · Nature · 2015 · 517 citations · Full text

Transcriptional Regulation, Lineage Plasticity, Developmental Biology +8

Design, Synthesis, and Evaluation of Indolinones as Triple Angiokinase Inhibitors and the Discovery of a Highly Specific 6-Methoxycarbonyl-Substituted Indolinone (BIBF 1120)

Gerald J. Roth, Armin Heckel, Florian Colbatzky et al. · Journal of Medicinal Chemistry · 2009 · 229 citations · Full text

Combinatorial Chemistry, Chemoprevention Strategy, Triple Angiokinase Inhibitors +21

Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases

Frank Hilberg, Ulrike Tontsch-Grunt, Anke Baum et al. · Journal of Pharmacology and Experimental Therapeutics · 2017 · 103 citations · Full text

The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML

Daniel Gerlach, Ulrike Tontsch-Grunt, Anke Baum et al. · Oncogene · 2018 · 82 citations · Full text